Efficacy of intralesional corticosteroid versus autologous platelet rich plasma injection in the management of chronic plantar fasciitis

Divya Anil Kumar¹, Harsha Kumar Koramutla²*

¹Department of Orthopaedics, RVS Medical College Hospital, Chittoor, Andhra Pradesh, India
²Narayana Medical College, Nellore, Andhra Pradesh, India

Received: 25 June 2018
Revised: 28 July 2018
Accepted: 30 July 2018

*Correspondence:
Dr. Harsha Kumar Koramutla,
E-mail: drharshaortho@gmail.com

ABSTRACT

Background: Plantar fasciitis is a common pathological condition affecting the hind foot, and a common cause of heel pain. The present study was taken up to assess the efficacy of intralesional corticosteroid compared to autologous platelet rich plasma injection in the management of chronic plantar fasciitis.

Methods: Patients were randomized into two groups (Group A and Group B) of 30 each. Group A received Corticosteroid injection while Group B received PRP injection. Patients were assessed functionally using American Orthopaedic Foot and ankle score (AOFAS), Visual analogue scale (VAS) scores before treatment and on follow-up visit at 6 weeks, 3rd month, and 6th month. Ultrasound of heel for plantar fascia thickness was measured before treatment and follow up visit at 6th month.

Results: A significant decrease in VAS score was observed in the corticosteroid group compared to PRP group at 6 weeks while the VAS score continued to decrease in the PRP group at 3 months and 6 months with an increase in the corticosteroid group at 3 months and 6 months. A significant increase in AOFAS was observed in the Corticosteroid group compared to PRP group at 6 weeks which increased in the PRP group at 3 months and 6 months. However it decreased in the corticosteroid group at 3 months and 6 months. Ultrasonographic evaluation showed improvement in fascial thickness in both the groups, but was better in the PRP group.

Conclusions: To conclude our study shows that corticosteroid is more effective for short term relief and PRP is more effective for long term relief.

Keywords: Plantar fasciitis, Platelet-rich plasma, Corticosteroids

INTRODUCTION

Plantar fasciitis is an important clinical cause of inferomedial heel pain in adults which occurs due to overuse injury arising due to multiple factors.¹,² There is often inflammation at the origin of the plantar fascia and surrounding perifascial structures, such as the calcaneal periosteum.³,⁴ Mechanical overload can eventually lead to chronic inflammation and degenerative changes.⁵ Combination of treatment modalities is usually recommended over any individual treatment option.⁶ Mechanical interventions like foot orthoses, foot taping, footwear, night splints, rest, and walking casts have been thought to reduce the load and stress applied to the inflamed plantar fascia to a tolerable level.⁷,⁸ Other treatment options include drugs such as non-steroidal anti inflammatory drugs (NSAIDS) to relieve pain and steroid injections.⁹,¹⁰ Night splints, low dye taping, heel pads, cups and orthoses have also been used with varying success rates.¹¹,¹² Extra corporeal shock wave therapy is used in the recent years to treat this disease with life style modifications.¹³ Only 5 to 10% of the people will need
surgical intervention like removal of calcaneal spur, neurectomy and plantar fasciotomy. Among the above mentioned treatments, steroid injection is a popular method of treating the condition but is useful in the short term with disappointing long-term results. Potentially disabling complications have also been reported, such as rupture of the plantar fascia, infection, and fat pad atrophy. Platelet rich plasma (PRP) is recently being recommended for treatment of plantar fasciitis. It has been shown to cause early relief from pain and is associated with improved functional activities of the patient compared to the other treatment modalities available. Platelet rich plasma is defined as a volume of the plasma fraction of autologous blood having a platelet concentration above baseline. Injecting an aliquot of concentrated platelet enriched plasma into a localized area introduces platelets into the tissue to stimulate a supra-physiologic release of growth factors. This initiates the regenerative process in degenerative conditions and thereby reduces pain. There are only a few studies which have shown the efficacy of PRP to treat plantar fasciitis when compared to other agents. In this study we have tried to compare the efficacy of intraslesional corticosteroid vs autologous platelet rich plasma injection in the management of chronic plantar fasciitis.

METHODS

Sixty patients were studied in this randomized controlled study conducted from September 2015 to September 2016 at PES Institute of Medical Sciences & Research, Kuppam. Patients were randomized into two groups (Group A and Group B) of 30 each by computer generated random numbers using the “sealed opaque envelope” technique. All patients were diagnosed as plantar fasciitis by clinical and radiological evaluation i.e. presenting complaint of plantar heel pain longer than 6 weeks, plantar fascia thickness >4 mm at the area of maximal tenderness (ultrasound of heel for plantar fascia thickness), failed conservative management of at least 4 weeks duration. Patients with history of severe anaemia, thrombocytopenia and those not willing to participate were excluded from the study.

Group-A (30 patients) were given Corticosteroid injection, Group-B (30 patients) were given PRP injection. Patients in group A (corticosteroid group) were given 2 ml (80 mg) Depomedrol injected along with 0.5ml of plain 2% xylocaine using 20 G wide bore needle into the point of maximum tenderness. Post injection, patients were asked to take rest for 15 min and then allowed to walk.

PRP preparation and administration

For the preparation of P-PRP, blood was withdrawn from cubital vein with help of BD vacutainer eclipse in three BD vacutainer tubes which is a 2.7 ml tube that contains 0.35 ml of 3.2% sodium citrate, an anticoagulant and volume of approximately 2.35 ml for whole blood. It was prepared using a 2-spin technique. In the 1st low spin step blood is centrifuged at 1200 rpm for 10 min in a Routine 380 R centrifuge model (Hettich, Zentrifugen). After the formation of three layers (a bottom layer composed of RBC; an upper layer composed of plasma, platelets and some WBCs; and an intermediate layer, or buffy coat, composed mostly of WBCs), the upper layer just above Buffy coat was collected with a 10 ml syringe. This collection was performed carefully to avoid disturbing the bottom layer of RBC and the buffy coat layer. Depending on the centrifugal force of the spin, the collected volume ranged from 0.75 ml to 1.25 ml in each BD vacutainer. Approximately 1 ml of the upper layer of the sample that underwent the first spin step was collected and transferred to one empty tube (approximately 3 ml). The tube is centrifuged again for 10 min at 2400 rpm. The upper half of the plasma volume, platelet poor plasma (PPP), was removed. The remaining volume of PPRP was used for injection. Platelet count was estimated by a pathologist. The PRP is randomly checked for number of platelets by Neubauer’s chamber or auto analyser. Most of the samples had a platelet count more than 1,000,000/ul in 5 ml volume that is 5 times the baseline. After this the PRP is shaken by just turning the tube 2 to 3 times to mix the platelets.

PRP injection technique

The procedure was explained to the patient and consent was obtained. With the patient in supine position, the involved foot was identified. The part was cleaned and prepared with sprit and povidone iodine. The site of maximal tenderness i.e medial aspect of the foot at the origin of plantar fascia usually was marked using a marker. One ml of 2% plain xylocaine was infiltrated into the skin and subcutaneous tissue. Dry needleling, also called peppering, was used to locally “injure” the soft tissue to stimulate the inflammatory response. Concomitant delivery of the PRP then modulates (enhances) the healing response. Each marked point of tenderness is penetrated with a 20-gauge needle until the underlying periostium is touched. A gristly, crunchy texture is audibly and palpably noted as the needle is advanced. After contacting the periostium, the needle is gently partially withdrawn then advanced in a fan-like wheel (peppering) the area 7 to 10 times. Next, 1 ml of the PRP is injected as this peppering manoeuvre is continued. This process is then carried out at each marked site.

Post injection care

Post injection, patients were rested for 15 min and then allowed to walk. As PRP effectively induces an inflammatory response, some patients experienced minimal to moderate discomfort following the injection which usually lasts for up to 1 week. They were instructed to ice the injected area if needed for pain control and modify activity as tolerated. We recommended acetaminophen as the optimal analgesic, and avoided use of NSAID’s.
After 48 hours, patients were given a standardized stretching protocol to follow for 2 weeks. A formal strengthening program was initiated after this stretching. Patients were advised to avoid strenuous activities and rest for 2 weeks. No aggressive running or jumping activities were allowed for 2 weeks. At 4 weeks after the procedure, patients were allowed to proceed with normal sporting or recreational activities as tolerated. Any type of foot orthoses was not be allowed.

Patients assessed functionally using American Orthopaedic Foot and ankle score (AOFAS), Visual analogue scale (VAS) scores and radio logically by Ultrasound of the heel for plantar fascia thickness,\(^{23,24}\) The AOFAS, VAS scores recorded before treatment and on follow-up visit at 6 weeks, 3rd month, and 6th month. Ultrasound of heel for plantar fascia thickness measured before treatment and follow up visit at 6th month.

**Statistical analysis**

Data was coded and entered into Microsoft excel data sheet and analysis was done by using SPSS 11 software. Data is expressed as mean±standard deviation for continuous variables and as frequency (number [%]) for categorical variables. All statistical analysis were performed using Microsoft excel spreadsheets (Microsoft, Redmond, WA USA). Independent samples T test was used to compare the mean difference between two groups, paired samples T test was used to compare the mean difference between paired data. Karl Pearson’s correlation analysis was used to determine the relationships between two continuous variables of interest. All statistical analysis will be performed using Microsoft excel spreadsheets (Microsoft, Redmond, WA USA) and Statistical package for social sciences for windows version 11.0 (SPSS Inc., Chicago IL, USA). A ‘p’ value <0.05 will be considered as statistically significant.

**RESULTS**

One patient from the PRP group discontinued at the end of the 6 months while two patients discontinued from the corticosteroid group. As shown in Table 1, female patients were more in both the groups [n=15 (51.72%) in Group A and n=16 (57.14%) in Group B]. In the study it was observed that among PRP group right heel was involved in 48%, while left heel involvement was seen in 52% of the study subjects. In the steroid group, right heel was involved in 54% while left heel involvement was seen in 46%.

**Table 1: Baseline characteristics of the study population.**

|                                | PRP group   | Corticosteroid group |
|--------------------------------|-------------|----------------------|
| Number of patients             | 29          | 28                   |
| Age                            | 40.27±8.03  | 39.35 ±12.52         |
| Females n,%                    | 15 (51.72)  | 16 (57.14)           |
| Right heel n,%                 | 14 (48.28)  | 15 (53.57)           |
| Left heel n,%                  | 15 (51.72)  | 13 (46.43)           |
| Baseline VAS score             | 7.137       | 7.214                |
| Baseline AOFAS                 | 54±4.117    | 55.63±4.34           |
| Plantar fascia thickness, mm   | 5.73        | 5.60                 |

AOFAS = American Orthopaedic Foot and ankle score; PRP= Platelet rich plasma; VAS= Visual analogue scale.

**Table 2: Visual analogue score in the groups studied.**

|                                | PRP group (n=29) | Corticosteroid group (n=28) |
|--------------------------------|------------------|-----------------------------|
| Pre treatment                  | 7.137            | 7.214                       |
| 6 weeks                        | 2.62             | 1.928                       |
| 3 months                       | 1.931            | 2.89                        |
| 6 months                       | 1.413            | 3.785                       |

PRP= Platelet rich plasma; VAS= Visual analogue scale.

As shown in Table 2 and 3, a significant decrease in VAS was observed in the corticosteroid injection group at 6 weeks compared to the PRP group (p=0.007). However, at the end of 3 months, the VAS increased in Corticosteroid group) and further decreased in PRP group (p=0.001) (Figure 1). A significant reduction in the VAS was obsered in the PRP group at the end of 6 months, compared to the corticosteroid group (3.78) (p=0.001). This shows that corticosteroid is more effective for short term relief and PRP is more effective for long term relief.

**Table 3: Pain severity in the groups studied.**

|                    | Pre treatment | 6th week | 3rd month | 6th month |
|--------------------|--------------|----------|-----------|-----------|
|                    | PRP (%)      | PRP (%)  | PRP (%)   | PRP (%)   |
| No pain (VAS-0)    | 0            | 0        | 0         | 0         |
| Mild pain (VAS-1,2,3) | 0            | 0        | 14 (48.28)| 23 (82.14)| 24 (82.76)| 10 (35.71)| 20 (68.97)| 6 (21.43)|
| Moderate pain (VAS- 4,5,6) | 10 (34.48) | 6 (21.43)| 15 (51.72)| 5 (17.86)| 5 (17.29)| 18 (64.29)| 4 (13.79)| 22 (78.57)|
| Severe pain (VAS- 7,8,9) | 19 (65.52) | 22 (78.57)| 0         | 0         | 0         | 0         | 0         | 0         |
| Worst pain (VAS- 10) | 0            | 0        | 0         | 0         | 0         | 0         | 0         | 0         |

P value 0.273

PRP= Platelet rich plasma; VAS= Visual analogue scale.
Table 4: AOFAS score in the groups studied.

| AOFAS score | PRP Group (n=29) | Corticosteroid group (n=28) | P value |
|-------------|------------------|-----------------------------|---------|
| Pre treatment | 54±4.117 | 55.63±4.34 | 0.9442 |
| 6 Weeks | 79.3±2.36 | 86.06±2.69 | 0.0155 |
| 3 Months | 85.72±2.36 | 78.57±1.91 | 0.001 |
| 6 Months | 90.03±3.37 | 74.67±3.69 | 0.001 |

PRP = Platelet rich plasma; AOFAS = American Orthopaedic Foot and Ankle score

Table 5: Plantar fascia thickness at various intervals in the groups studied.

| Average plantar fascia thicknesses in each group | PRP group (n=29) | Corticosteroid group (n=28) |
|-----------------------------------------------|------------------|-----------------------------|
| Pretreatment (mm) | 5.73 | 5.60 |
| 6 Months (mm) | 3.35 | 3.75 |
| % reduction fascia thickness | 41.54 | 33.04 |

PRP = Platelet rich plasma.

As shown in Table 5, ultrasonographic evaluation showed that both the groups had similar baseline plantar fascia thickness prior to injection. After 6 months of injection, the PRP group had a significant reduction in the thickness of plantar fascia compared to corticosteroid group (p<0.001).

DISCUSSION

The present study aimed to compare the efficacy of intralesional corticosteroid vs autologous platelet rich plasma injection in the management of chronic plantar fasciitis; a very common musculoskeletal problem encountered in orthopaedic day today practice. Plantar fasciitis accounts for 11 to 15% of all foot problems in adults and peaks between 40 to 60 years. The patients in our study had a mean of 40 years (range: 27-51 years). Other studies have reported a mean age between 38 to 46 years. Females were more frequently affected (52% in PRP group and 57% in the corticosteroid group) in our study. Though gender differences have not been shown in patients with planter fasciitis, a recent study observed a slight male preponderance (57.5%) contrary to our finding.

Various studies have reported the use of PRP in the treatment of plantar fasciitis and have also compared the effectiveness of PRP and Corticosteroid injections. Initially thought to be an inflammatory disease, plantar fasciitis is now known to occur due to multiple etiologies including anatomical, biochemical and environmental factors. Often a combination of factors are involved. The term fasciosis has been recommended owing to the chronicity of the disease and the evidence of degeneration rather than inflammation. The treatment modalities also vary owing to the different etiologic factors. Conservative approaches such as NSAIDs, low dye taping, heel pads, cups, orthoses, soft soled shoes and night splints, take few weeks to months for the healing.
However, most of them have limited scientific evidence of their efficacy.

Corticosteroids are recommended owing to their strong anti-inflammatory effect. Corticosteroids act through inhibition of fibroblast proliferation and ground substance protein expression fasciitis. PRP being rich in platelets provide a higher concentration of the bioactive growth factors reported to promote healing. Many growth and differentiation factors are released from the alpha granules, which are the storage units found in platelets. In vivo and in vitro researches also suggest that PRP induces over expression of additional endogenous growth factors beyond what is contained within the platelet concentrate. The potential benefits of PRP are thought to rely on intrinsic properties and interplay between the concentrated growth factors. Some of these important growth factors include platelet derived endothelium growth factors, transforming growth factors-β, vascular endothelium growth factors, fibroblast growth factors, epidermal growth factor and insulin like growth factor-1. Complex interaction of these growth and differentiation factors, along with adhesive protein factors such as fibronectin and vitronectin are what is responsible for the healing response, promoting the long regenerative process of chemotaxis, cell proliferation, removal of tissue debris, angiogenesis, extracellular matrix formation, osteoid production and collagen synthesis. The needle induced bleeding during injection provides the clotting factor thrombin needed to activate platelets. Thus PRP accelerates the physiological process of healing.

On subjective assessment of the treatment modalities using VAS score, we found that corticosteroid is more effective for short term relief and PRP is more effective for long term relief as evidenced by a significant decrease in VAS score (p<0.001) in the corticosteroid group (1.92) as compared to PRP group (2.62) at 6 weeks while the VAS score continued to decrease in the PRP group at 3 months (1.93) and 6 months (1.41) and increased in the corticosteroid group at 3 months (2.89) and 6 months (3.78). This is in agreement with an earlier study reported. VAS score to be significantly reduced in both PRP and corticosteroid groups at one month, but at 3 months following treatment it increased in Corticosteroid group and remained constant in PRP group till 6 months. Other studies have reported superior results of PRP over corticosteroid therapy. A recent study has reported both the therapies to be equally effective. Others also have reported equal efficacy for both PRP and corticosteroid therapy.

Functional assessment in terms of the AOFAS score also showed that corticosteroid is more effective for short term relief and PRP is more effective for long term relief as evidenced by a significant increase in AOFAS in the Corticosteroid group compared to PRP group at 6 weeks (p<0.001) which increased in the PRP group at 3 months (85.72) and still further increased at 6 months (90.03). However it decreased in the corticosteroid group at 3 months (78.57) and 6 months (74.67). Previous studies have reported improvement or no change on follow-up. Jain et al have reported an improvement in both the groups but the change was not statistically significant between the groups. However the duration of follow-up was for a longer time; 2 years in one study.

Ultrasonographic evaluation is commonly employed for to assess the thickness of the plantar fascia and is of diagnostic significance. The thickness improved in both the groups. However, PRP group showed a better improvement in the thickness of the plantar fascia compared to the corticosteroid group in our study. However, Jain et al observed plantar fascia thickness to be reduced more quickly in patients who received corticosteroid injection compared to those who received a PRP injection at 3 months. The decrease was however comparable at 6 months follow-up. We have assessed the plantar fascia thickness at baseline and at 6 months. Other studies have shown effectiveness of both the treatment modalities in decreasing the plantar fascia thickness.

To conclude, our study shows that PRP injection is more effective treatment for long term relief of chronic heel pain. Thus, PRP could be a biological option for a common orthopaedic and recalcitrant orthopaedic problem like heel pain/plantar fasciitis.

Limitation

The small sample size and the shorter duration of follow-up of the study are the important limitations. Also, variability of platelet concentration from patient to patient is another limitation. The findings need to be confirmed in larger prospective studies with a longer duration of follow-up.

Funding: No funding sources  
Conflict of interest: None declared  
Ethical approval: The study was approved by the institutional ethics committee

REFERENCES

1. Cornwall MW, McPoil TG. Plantar fasciitis: Etiology and treatment. J Ortho Sports Phys Ther. 1999;9:756.
2. Cullen NP, Singh D. Plantar fasciitis: a review. Br J Hosp Med (Lond).2006;67:72-6.
3. Young CC, Rutherford DS, Niedfelt MW. Treatment of plantar fasciitis. Am Fam Physician. 2001;63:467-74,477-8.
4. Kaya BK. Plantar fasciitis. J Sport Rehabil. 1996;5:305-20.
5. Healey K, Chen K. Plantar fasciitis: current diagnosis modalities and treatments. Clin Podiatr Med Surg. 2010;27:369-80.
6. Wolgin M, Cook C, Graham C, Mauldin D. Conservative treatment of plantar heel pain: long-term follow-up. Foot Ankle Int.1994;15:97-102.
7. Lynch DM, Goforth WP, Martin JE, Odom RD, preece CK, Kotter MW. Conservation treatment of plantar of plantar fascitis. A prospective study. J Am Podiatr Med Assoc. 1998;88:375-80.
8. Stuber K, Kristmanson K. Conservative therapy for plantar fasciitis: a narrative review of randomized controlled trials. J Can Chiropr Assoc. 2006;50(2):118-33.
9. Glazer JL. An approach to the diagnosis and treatment of plantar fasciitis. Foot Ankle Int. 1996;17:57-532.
10. Crawford F, Atkins D, Young P, Edwards J. Steroid injection for heel pain: evidence of short-term effectiveness. A randomized controlled trial. Rheumatology (Oxford, England) 1999;38(10):974-7.
11. Wheeler PC. The addition of a tension night splint to a structured home rehabilitation programme in patients with chronic plantar fasciitis does not lead to significant additional benefits in either pain, function or flexibility: a single-blinded randomised controlled trial. BMJ Open Sport — Exercise Medicine. 2017;3(1):e000234.
12. Landorf KB, Keenan AM, Herbert RD. Effectiveness of foot orthoses to treat plantar fasciitis: a randomized trial. Arch Intern Med. 2006;166(12):1305–10.
13. Vahdatpour B, Sajadieh S, Bateni V, Karami M, Sajjadieh H. Extracorporeal shock wave therapy in patients with plantar fasciitis. A randomized, placebo-controlled trial with ultrasonographic and subjective outcome assessments. Journal of Research in Medical Sciences : Off J Isfahan Univ Med Sci. 2012;17(9):834-8.
14. El Shazly O, El Beltagy A. Endoscopic plantar fascia release, calcaneal drilling and calcaneal spur removal for management of painful heel syndrome. Foot (Edinb). 2010;20(4):121-28.
15. O’Malley MJ, Page A, Cook R. Endoscopic plantar fasciotomy for chronic heel pain. Foot Ankle Int. 2000;21:505-10.
16. Tatli YZ, Kapasi S. The real risks of steroid injection for plantar fasciitis, with a review of conservative therapies. Curr Rev Musculoskeletal Med. 2009;2(1):3-9.
17. Yang WY, Han YH, Cao XW, Pan JK, Zeng LF, Lin JT, et al. Platelet-rich plasma as a treatment for plantar fasciitis: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2017;96(44):e8475.
18. Amable PR, Carias RBV, Teixeira MVT, da Cruz Pacheco, Corrêa do Amaral RJF, Granjeiro JM, et al. Platelet-rich plasma preparation for regenerative medicine: optimization and quantification of cytokines and growth factors. Stem Cell Res Ther. 2013;4(3):67.
19. Peerbooms JC, Sluima J, Bruijn DJ, Gosens T. Positive effect of an autologous platelet concentrate in plantar fasciitis in a doubleblind randomized controlled trial: platelet rich plasma versus corticosteroid injection with a 1 year follow up. Am J Sports Med. 2010;38:255-62.
20. Martinelli N, Marinozzi A, Cami S, Trovato U, Bianchi A, Denaro V. Platelet-rich plasma injections for chronic plantar fasciitis. Int Orthop. 2013;37(5):839-42.
21. Gupta M, Manfatkar C, Patil S. To compare the efficacy and role of local corticosteroid injection and local injection of platelet rich plasma in the treatment of plantar fasciitis. Indian J Appl Res. 2015;5(2).
22. Tiwari M. Platelet rich plasma therapy: A comparative effective therapy with promising result in plantar fasciitis. J Clin Orthop Trauma. 2013;4:31-5.
23. Jain SK, Suprashtant K, Kumar S, Yadav A, Kearns SR. Comparison of Plantar Fasciitis Injected With Platelet-Rich Plasma vs Corticosteroids. Foot Ankle Int. 2018;39(7):780-6.
24. Kitaoka HB, Alexander IJ, Adelaar RS, Nunley JA, Myerson MS, Sanders M. Clinical rating systems for the ankle-hindfoot, midfoot, hallux, and lesser toes. Foot Ankle Int. 1994;15:349–53.
25. McCormack HM, Horne DJ, Sheather S. Clinical applications of visual analogue scales: a critical review. Psychol Med. 1988;18:1007-19.
26. Acosta-Olivo C, Elizondo-Rodriguez J, Lopez-Cavazos R, Vilchez-Cavazos F, Simental-Mendoza M, Mendoza- Lemus O. Plantar fasciitis: a comparison of treatment with intraslesional steroids versus platelet-rich plasma (PRP). A randomized, blinded study. J Am Podiatr Med Assoc. 2016;107(6):490-6.
27. Akşahin E, Doğruyol D, Yokuş HY, Yüksel HY, Hapa O, Doğan O, et al. The comparison of the effect of corticosteroids and platelet-rich plasma (PRP) for the treatment of plantar fascitis. Arch Orthop Trauma Surg. 2012;132(6):781-5.
28. Ragab EM, Othman AM. Platelets rich plasma for treatment of chronic plantar fasciitis. Arch Orthop Trauma Surg. 2012;132(8):1065-70.
29. Barrett S, Errwedge S. Growth factors for chronic plantar fasciitis. Podiatry Today. 2013;17:37-4215.
30. Dyck DD Jr, Boyajian-O’Neill LA. Plantar fasciitis. Clin J Sport Med. 2004;14(5):305-9.
31. Thomas JL, Christensen JC, Kravitz SR, Mendicino RW, Schuberth JM, Vanore JV, et al. American College of Foot and Ankle Surgeons heel pain committee. The diagnosis and treatment of heel pain: a clinical practice guideline-revision. J Foot Ankle Surg. 2010;49(3 Suppl):S1-19.
32. McMillan AM, Landorf KB, Gilheany MF, Bird AR, Morrow AD, Menz HB. Ultrasound guided injection of dexamethasone versus placebo for treatment of plantar fasciitis: protocol for a randomised controlled trial. J Foot Ankle Res. 2010;3:15.
33. Mahindra P, Yamin M, Selhi HS, Singla S, Soni A. Chronic Plantar Fasciitis: Effect of Platelet-Rich
34. Monto RR. Platelet-rich plasma efficacy versus corticosteroid injection treatment for chronic severe plantar fasciitis. Foot Ankle Int. 2014;35(4):313-8.

35. Radwan A, Wyland M, Applequist L, Bolowsky E, Klingensmith H, Virag I. Ultrasonography, an effective tool in diagnosing plantar fasciitis: a systematic review of diagnostic trials. Int J Sports Phys Ther. 2016;11(5):663-71.

36. Tsai WC, Hsu CC, Chen CP, Chen MJ, Yu TY, Chen YJ. Plantar fasciitis treated with local steroid injection: comparison between sonographic and palpation guidance. J Clin Ultrasound. 2006;34(1):12-6.

Cite this article as: Kumar DA, Koramutla HK. Efficacy of intralesional corticosteroid versus autologous platelet rich plasma injection in the management of chronic plantar fasciitis. Int J Res Orthop 2018;4:790-6.